Left-sided endocarditis caused by Pseudomonas aeruginosa: Successful treatment with meropenem and tobramycin

Diagnostic Microbiology and Infectious Disease

Volumn 47, Issue 2, 2003, Pages 427-430

  Gavin, P J ^a   Suseno, M T ^a   Cook, F V ^a   Peterson, L R ^a   Thomson Jr , R B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Meropenem; Pseudomonas endocarditis

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; AZTREONAM; CARBENICILLIN; CARBENICILLIN PLUS POLYMYXIN; CEFTAZIDIME; CEFTAZIDIME PLUS TOBRAMYCIN; CEFTRIAXONE; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; DIGOXIN; GENTAMICIN; KANAMYCIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; POLYMYXIN; POLYMYXIN PLUS TETRACYCLIN; SULFAFURAZOLE; TAZOBACTAM; TETRACYCLINE; TICARCILLIN; TICARCILLIN PLUS AMIKACIN; TICARCILLIN PLUS TOBRAMYCIN; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADULT; ANAMNESIS; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BLOOD CHEMISTRY; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESPONSE; FEVER; GRAM NEGATIVE BACTERIUM; HEMOPTYSIS; HUMAN; LABORATORY TEST; MALE; MENTAL PATIENT; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERODIAGNOSIS; SYMPTOM; THORAX RADIOGRAPHY;

ADULT; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS; TOBRAMYCIN;

EID: 1642309733     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(03)00135-4     Document Type: Article

References (22)

1. Astra-Zeneca Pharmaceuticals. (2001). Merrem. (Meropenem). Prescribing information. Wilmington, DE
2. Bayer A.S., Crowell D.J., Yih J., Bradley D.W., Norman D.C. Comparative pharmacokinetics and pharmacodynamics of amikacin and ceftazidime in tricuspid and aortic vegetations in experimental Pseudomonas endocarditis. J Infect Dis. 158:(2):1988;355-359.
3. Bowker K.E., Holt H.A., Reeves D.S., MacGowan A.P. Bactericidal activity, post-antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations. J Antimicrobiol Chemother. 38:1996;1055-1060.
4. Bustamente C., Drusano G., Tatem B., Standiford H. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antmicrob Agents Chemother. 26:1984;678-682.
5. Cabinian A.E., Kaatz G.W. Successful therapy of Pseudomonas aeruginosa endocarditis with ceftazidime. Amer J Med. 83:1987;366-367.
6. Costerton J. The etiology and persistence of cryptic bacterial infections A hypothesis. Rev Infect Dis. 6:(Supplement 3):1984;S608-S616.
7. Craig W.A. The pharmacology of meropenem, a new carbepenem antibiotic. Clin Infect Dis. 24:(Suppl 2):1997;S266-S275.
8. D'Amato R.F., Hochstein L., Vernaleo J.R., Cleri D.J., Wallman A.A., Gradus M.S., Thornsberry C. Evaluation of the BIOGRAM antimicrobial susceptibility test system. J Clin Microbiol. 22:1985;793-798.
9. Diaz C.R., Fossieck B.E., Parker R.H. Pseudomonas endocarditis: Cure with carbenicillin and polymyxin B. South Med J. 70:1977;869-871.
10. Iaconis J.P., Pitkin D.H., Sheikh W., Nadler H.L. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials. Clin Infect Dis. 24:(Suppl 2):1997;S191-A196.
11. Ingerman M.J., Pitsakis P.G., Rosenberg A.F., Levison M.E. The importance of pharmacodynamics in determining the dosing interval in therapy for experimental Pseudomonas endocarditis in the rat. J Infect Dis. 153:(4):1986;707-714.
12. Jimenez-Lucho V.E., Saravolatz L.D., Medieros A.A., Pohlod D. Failure of therapy in Pseudomonas endocarditis selection of resistant mutants. Clin Infect Dis. 154:(1):1986;64-68.
13. Komshian S.V., Tablan O.C., Palutke W., Reyes M.P. Characteristics of left-sided endocarditis due to Pseudomonas aeruginosa in the Detroit medical Center. Rev Infect Dis. 12:(4):1990;693-702.
14. Lloyd K.M., Gordon J.N. Bacterial endocarditis due to Pseudomonas aeruginosa. Ann Intern Med. 55:1961;814-817.
15. Moon Y.S., Chung K.C., Gill M.A. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin Infect Dis. 24:(Suppl 2):1997;S249-S255.
16. National Committee for Clinical Laboratory Standards (2002). Performance standards for antimicrobial susceptibility testing; Twelfth Informational Supplement. NCCLS document M 100-S12
17. National Committee for Clinical Laboratory Standards (1999). Methododology for the Serum Bactericidal Test; Approved Guideline; NCCLS document M 21-A;1999
18. Norrby S.R., Gildon K.M. Safety profile of meropenem A review of nearly 5, 000 patients treated with meropenem. Scand J Infect Dis. 31:1999;3-10.
19. Pfaller M.A., Jones R.N. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated worldwide. Diagn Microbiol Infect Dis. 28:1997;157-163.
20. Reyes M.P., Lerner A.M. Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa. Clin Infect Dis. 5:(2):1983;314-321.
21. Reyes M.P., Lerner A. Synergy between carbenicillin and an aminoglycoside (gentamicin or tobramycin) against Pseudomonas aeruginosa isolated from patients with endocarditis and sensitivity of isolates to normal human serum. J Infect Dis. 140:(2):1979;192-202.
22. Wieland M., Lederman M.M., Kline-King C., Keys T.F., Lerner P.I., Bass S.N., Chmielewski R., Banks V.D., Ellner J.J. Left-sided endocarditis due to Pseudomonas aeruginosa. Medicine. 65:(3):1986;180-189.